Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Matriks Bilgi Dagitim Hizmetleri AS
IST:MTRKS.E
|
TR |
|
G
|
Great Boulder Resources Ltd
ASX:GBR
|
AU |
|
Vale SA
BOVESPA:VALE3
|
BR |
|
D
|
Dialog Group Bhd
KLSE:DIALOG
|
MY |
Novan Inc
Net Income (Common)
Novan Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Net Income (Common)
-$31.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$26.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Net Income (Common)?
Net Income (Common)
-31.3m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Net Income (Common) amounts to -31.3m USD.
What is Novan Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
3%
Over the last year, the Net Income (Common) growth was -5%. The average annual Net Income (Common) growth rates for Novan Inc have been -1% over the past three years , 3% over the past five years .
